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Synthesis and antiproliferative activity of new
tonantzitlolone-derived diterpene derivatives†
Torsten Busch,a Gerald Dräger,a Eike Kunst,a Hannah Benson,a Florenz Sasse,b
Karsten Siemsc and Andreas Kirschning*a
The synthesis of the diterpene (+)-tonantzitlolone A and a series of derivatives is reported. The study
includes the determination of their antiproliferative activities against selected cancer cell lines.
1. Introduction
The endemic Mexican medical plant Stillingia sanguinolenta
has been found to be a rich source for a wide range of ter-
penes.1 Structurally, the two diterpenes tonantzitlolone A (1)
and B (2; OAc at C-4′ of side chain) are the most remarkable
secondary metabolites from Stillingia sanguinolenta.
Noteworthy, diterpene cyclases rarely generate 15-membered
cyclization products – the backbone is commonly named the
flexibilan skeleton (3) – as found in tonantzitlolones A (1) and
B (2) (Fig. 1).
The roots of S. sanguinolenta are used in poultices after
childbirth, and northern Mexican natives recommend infu-
sions of leaves for the treatment of pulmonary ailments. Native
American tribes of Navajos and Creek used the closely related
S. sylvatica in a similar fashion.2,3 Indeed, tonantzitlolone also
occurs in the roots of S. sylvatica and in Sebastiana macrocarpa.
Importantly, the isolation of six additional tonantzitlolone
derivatives from the endemic Mascarene species Stillingia
lineata was reported recently by M. Litaudon and coworkers.4
We showed that tonantzitlolone A and its enantiomer exert
cytostatic activity on tumor cells.5 They induce monoastral
half-spindle formation suggesting inhibition of the mitotic
motor protein kinesin-5. Interestingly, they are no general
kinesin inhibitors as they do not affect kinesin-1 function.
This was an important finding, also because motor proteins
are involved in many fundamental eukaryotic cell processes
such as the transport of vesicles and cell organelles, as well as
the organisation and structure of the spindle apparatus during
cell devision.6 Consequently, targeting of kinesins with small
molecules is regarded to be an important strategy in antitumor
research and monastrol as well as HR22C16 are classical
examples of such inhibitors.7
Tonantzitlolone is one diterpene example8 that exerts cyto-
static activity, the most famous being paclitaxel (4), first iso-
lated from the bark of the yew tree Taxus brevifolia found on
the Northpacific coast. It is used as a clinical drug (Taxol®)
against several solid tumors (e.g. mamma, prostate, ovarian
cancer). Secondly, eleutherobin (5) is a marine diterpene glyco-
side collected from the soft coral Eleutherobia cf. albiflora
which exerts strong antiproliferative activity against cancer cell
lines (IC50 = 10–15 nM) by stabilizing microtubules like pacli-
taxel (4).
Although the diterpenoid core structures of these three
diterpenes differ, they all contain a small ester side chain
(marked in grey) that is essential for the biological activity.7
Based on our important findings that tonantzitlolone A (1) can
Fig. 1 Structures of tonantzitlolone A (1) and B (2), paclitaxel (4) and
eleutherobin (5) as well as schematic representation of the flexibilane
backbone (3) (numbering of the tonantzitlolones as defined in the
original paper on the isolation and structure elucidation).
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act on mitotic motor protein kinesin-5 an important target in
cancer therapy we extended our investigations on the prepa-
ration of tonantzitlolone A (1) and new derivatives that differ
in the side chain including the incorporation of the side
chains found in paclitaxel (4) and eleutherobine (5) thereby
creating derivatives that are occasionally called hybrids com-
posed of structural elements found in two different natural
products or drugs.9 Synthetically, we made use of the principal
approach reported in our first successful total synthesis of the
enantiomer of tonantzitlolone A (ent-1).10 It was supposed to
provide sufficient amounts of the diterpene.
2. Results and discussion
Synthesis of tonantzitlolone
The synthesis of tonantzitlolone started from methyl geranate
which was transformed into diester 7 via aldehyde 6 using the
O,O-ketene acetal 12 in the Kiyooka aldol reaction (Scheme 1).11
Yields and enantiocontrol were excellent. From here epoxy
alcohol 8 was prepared utilizing the Sharpless-epoxidation as
the key step. Next, acid catalyzed acetonide cleavage initiated
tetrahydrofuran formation which was followed by reacetaliza-
tion of the 1,2-diol moiety, overall with a high degree of stereo-,
regio and chemoselectivity. The next key step of the synthesis
was the aldol reaction that proceeded with high anti Felkin
control when the potassium enolate was employed. Thus,
ketone 10 was treated with KHMDS and in the reaction with
aldehyde 14 aldol product 18 was formed (dr = 18 : 1) via a
transition state (TS) that supposedly relies on chelation of the
furan oxygen atom (Scheme 2).12
The relative stereochemistry was determined after dibal-H
reduction to yield the 1,3-syn diol 22. Protection provided acet-
onide 23 that allowed us to prove the stereochemistry of the
stereotriade by determining key coupling constants ( J) and
NOe-contacts (Scheme 2).
The unexpected stereochemical outcome of this aldol reac-
tion is general. Indeed, we also utilized aldehydes 15–17,13
that contain a second alkene moiety or an alkyne group,
respectively, to furnish aldol products 19–21 again with excel-
lent diastereoselectivity (Scheme 2).
We included these aldol products into our studies because
we planned to utilize them in ring closing metatheses to
follow. These would result in macrocycles with a functiona-
lized olefinic double bond at C-4 and C-5 that could directly be
transformed into the targeted hydroxy ketone upon dihydroxy-
lation without tedious differentiation of the diol moiety.
However, at this point it needs to be noted that all efforts to
enforce ring closing metathesis using different Grubbs cata-
lysts failed.14 Problems of achieving olefin metathesis with
halogenated substrates have been discussed before.15
Aldol product 22 was converted into the corresponding
hydroxy ketone by a series of functional group manipulations
(desilylation, doubly silylation with TES-Cl, oxidation and desi-
lylation) that smoothly underwent ring closing metathesis to
yield macrocycle 24 (Scheme 3). Importantly, the RCM pro-
vided the (E)-alkene as major diastereoisomer. It allowed the
regioselective dihydroxylation of this less hindered olefin at
C4/C5 after TMS-protection of the 1,3-diol unit. This silylation
turned out to be beneficial for the step to follow as the yield
and the selectivity increased. Best facial selectivity in favour of
the desired (4R,5R)-diol 25 was achieved under Sharpless
dihydroxylation conditions using the simpler α-DHQ-CLB ligand.
It has to be noted that the 4 : 1 ratio represents the mismatched
case. The Z-diastereoisomer remained untouched under the
Scheme 1 Synthesis of ketone 10. Reagents and conditions: (a) 11 and
12, CH2Cl2, −85 °C to −40 °C, 0.5 h (90%, 99% ee); (b) LiAlH4, Et2O, 0 °C
to rt; (c) 2,2-dimethoxy propane, p-TsOH, 2.5 h, rt, H2O, 35 min (83% for
two steps); (d) L-(+)-diethyl tartrate, Ti(OiPr)4, t-BuOOH, molecular
sieves 4 Å, CH2Cl2, −15 °C, 0.5 h, then cooling to −25 °C and addition of
alkene, CH2Cl2, 20 h, 97%; (e) CH2Cl2, THF, (HOCH2)2, p-TsOH, 55 min,
then 2,2-dimethoxy propane, rt, 16 h, then addition of H2O, 15 min
(78%); (f ) TPAP, NMO, molecular sieves 4 Å, CH2Cl2, rt, 2.5 h (91%);
(g) 13, LDA, THF, −78 °C, then addition of aldehyde, −78 °C to rt, 39 h, Δ,
4.5 h (79%); (h) p-TsOH, MeOH/H2O (1 : 1), 6.5 h, 50 °C (>99%); (i) TBSCl,
imidazole, 4-DMAP, CH2Cl2, rt, 3 h (97%); ( j) Dess–Martin-periodinane,
CH2Cl2, 0 °C to rt, 6.5 h (94%).
Scheme 2 Aldol reaction with aldehydes 14–17 yield potential RCM
precursors 18–21. Reagents and conditions: (a) KHMDS, THF, −78 °C,
0.5 h then addition of aldehyde 14–17 in THF, 35 min; (b) 18, dibal-H;
(c) dimethoxypropane, TsOH, rt, 13 h (66% for two steps).
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dihydroxylation conditions. The equilibrium between ketone
25 obtained after removal of the TMS-protection and semi-
acetal 26 could only be shifted towards the desired pyranol under
acidic conditions. Next, the introduction of (E)-3-methylpent-2-
enoic acid became possible. This step was not regioselective
and provided ester 27 and 28 with preference for the C-4 posi-
tion. The hydroxy group at C10 remained untouched. The two
regioisomers could not be separated at this point so that this
step was coupled with the Ley–Griffith oxidation. This two step
protocol provided two final products: (a) tonantzitlolone 1 and
its regioisomer 29 in which the ester side chain is located at
C4 and C8, respectively while C10 remained untouched.
Depending on the location of the side chain, either C4 or C10
are oxidized in the final step. The isomers could be separated
by column chromatography. The synthetic sample of tonantzi-
tlolone (1) was identical with an authentic sample including
optical rotations: [α]D20 = +116° (c 0.5 in CHCl3) (authentic
material: [α]D20 = +134° (c 0.25 in CHCl3, ref. 1 and 10)).
Synthesis of tonantzitlolone derivatives, modified at C4
Tonantzitlolone A (1) served as a starting point for the prepa-
ration of a series of derivatives. With these we could carry out
preliminary structure–activity studies for this diterpene,
especially in view of it potency to inhibit the mitotic motor
protein kinesin-5.4
The keto group at C-4 can be condensed with several amino
containing agents to yield CvN derivatives thereby preserving
the sp2-character at C-4. However, simple amines like methyl
amine cannot be used as amino donors, because they yield
complex product mixtures. From these we could identify pro-
ducts that had undergone double bond migration to the
corresponding enone (C2–C4) as well as lactol opening with
transacylation and migration of the ester side chain most
likely to C-5.16,17 In contrast, two diastereomeric oximes 30a,b
become available after treatment of 1 with hydroxyl amine
(Table 1, entry 1). The E/Z-isomers are configurationally stable
and can easily be separated chromatographically. Their acyla-
Scheme 3 Total synthesis of tonantzitlolone (1). Reagents and con-
ditions: (a) TBAF 3 H2O, THF, rt, 45 min (>99%); (b) TES-Cl (excess), imi-
dazole, DMF, rt, 21 h then 50 °C, 3 h (89%); (c) Dess–Martin periodinane,
CH2Cl2, 0 °C to rt, 3 h (93%), then TBAF 3 H2O, THF, 0 °C, 20 min (92%);
(e) 10 mol% Grubbs-II, CH2Cl2, Δ, 1.5 h, (93%; E/Z ∼ 4 : 1); (f ) TMS-Cl
(excess), Et3N, DMF, 0 °C, (93%); (g) 10 mol% OsO4, 36 mol%
α-DHQ-CLB, K2CO3, MeSO2NH2, K3Fe(CN)6, tBuOH, H2O, 0 °C, 3 h, then
TBAF, THF, 0 °C, 15 min (97%, dr ∼ 4 : 1 for favored (4R,5R)-diastereo-
isomer); (h) PPTS, CH2Cl2, rt, 20 min (51% and 36% of a mixture with
starting material 4R,5R and 4S,5S); (i) HO2CCvC(Me)Et, DIC, DMAP,
CH2Cl2, rt, 17 h (45%); ( j) TPAP (cat.), NMO, 4 Å MS, CH2Cl2, rt, 40 min
(1: 21%, 29: 21%).
Table 1 Synthesis of tonantzitlolone derivatives 30–36, structure of derivative 37 and stereochemical assignments by NOe measurements
Entry Conditions Product, R E/Z-ratio Yield [%]
1 H2NOH, pr, rt, 12h 30a,b-OH 2 : 1 80
2 H2NO-allyl, pr, rt, 12h 31a,b-O-Allyl 6 : 1 35
a
3 H2N(CO)NH-NH3Cl (10 eq.), py, rt, 12h 32a,b-NH(CO)NH2 10 : 1 91
4 pH2NPh-(CO)NHNH2, py, 1N HCl, rt, 36 h 33a,b-NH(CO)pPhNH2 1 : 5 76
5 pHOPh-(CO)NHNH2, py, 1N HCl, rt, 4d 34a,b-NH(CO)pPhOH 1 : 9 79
6 3-Furyl-(CO)-NH-NH2, CH2Cl2, PTSA, MS 4A, 24 h, 40 °C 35a,b, –NH(CO)–3-furyl 1 : 4. 67
b
7 1 : 7 12
aHydroxyketone 37 formed which could in part be ring closed to the lactol [PPTS, CH2Cl2, rt, 6 h (35% 31a,b, 55% 37)].
b 19% starting material
reisolated.
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tion turned out to be difficult and no defined products were
isolated.
Also allyl oximes 31a,b were prepared from tonantzitlolone 1
but here the condensation reaction yielded the ring-opened
acetal 37. Ringclosure to the hemiacetals 31a,b could only be
enforced under acidic conditions (see also 25 → 26).
Additionally, also semicarbazones 32a,b and acyl hydrazides
33a,b–36a,b were prepared under standard condensation con-
ditions. The ratio of E/Z-diastereomers differed. Oximes and
semicarbazones 32a,b preferentially yielded E-configured
isomers, while the reaction with acyl hydrazines strongly
favoured the formation of Z-acyl hydrazides 33–36 as judged
from NOe-measurements.
The epimer 38 of dihydro tonantzitlolone 27 becomes avail-
able by reducing the keto group at C-4 in 1. Both diastereo-
meric hydro-tonantzitlolone A derivatives 27 and 38 are
generated with moderate substrate control, depending on the
reducing agent employed (Scheme 4).
Synthesis of tonantzitlolone derivatives with different ester
side chains
Tonantzitlolone precursor 26, in which the side chain is
missing, can be used to introduce other ester side chains
(Scheme 5). E.g., coupling with carboxylic acid 39,18 the side
chain in eleutherobin (5), under standard condensation con-
ditions yielded two unseparable regioisomeric esters 40 and
41 19 similar to the transformation 26 → 27/28 (Scheme 3).
Carefully conducted Ley–Griffith oxidation of this mixture only
exerted the transformation of regioisomer 41, while ester 40
was reisolated. Unexpectedly, the oxidation took place at C10
and not at C4 thereby yielding ketone 42. This observation is
difficult to rationalize. One may discuss two effects: (a) shield-
ing of position 4 by the side chain or (b) precoordination of
the oxidant to the imidazol moiety thereby directing it close to
the C10 position.
Next, we probed the introduction of the terminal polyketide
element of the antitumor agent epothilone (Scheme 6).20
(E)-2-Methyl-3-(2-methylthiazol-4-yl)acrylic acid 43 21 was coupled
with tonantzitlolone derivative 26 to exclusively yield the regio-
isomer 44 even when a 9-fold excess (with respect to 26) of the
carboxylic acid 43 was employed. The formation of the regio-
isomeric ester 46 could not be detected. Ley–Griffith oxidation
again selectively occurred at C10 to furnish ketone 45.
Finally, we also introduced the α-hydroxy-β-amino acid
present in the diterpene paclitaxel 4 utilizing the activated
β-lactam 47 22 (Scheme 7). In this case only the diester 48
could be isolated in small amounts after extensive HPLC puri-
fication. The reaction proceeded rapidly under basic con-
ditions but the product mixture was complex and NMR
analysis was hampered by line broadening. The small isolated
amounts of 48 stopped us to conduct the Ley–Griffith
oxidation.
Scheme 4 Reduction of the keto group at C-4. Reagents and con-
ditions: (a) dibal-H, CH2Cl2, −78 °C, (82%), or (b) polystyrene-
CH2NMe3BH4, MeOH, rt (90%).
Scheme 5 Preparation of tonantzitlolone derivatives 40–42. Reagents
and conditions: (a) CH2Cl2, DIC, rt, 1 h, then DMAP, 19 h (72%; 40 : 41 =
2 : 1); (b) TPAP, NMO, MS 4 Å, CH2Cl2, rt, 1.5 h (36%).
Scheme 6 Preparation of tonantzitlolone derivatives 44–46. Reagents
and conditions: (a) 43, CH2Cl2, DIC, rt, 16 h, then DMAP, 29 h (53%);
(b) TPAP, NMO, MS 4 Å, CH2Cl2, rt, 3.5 h (78%).
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The latter series of experiments reveal the difficulties in pre-
dicting and rationalizing the regio- and chemoselectivity of
even simple transformations on the periphery of multifunctio-
nalized natural product scaffolds or backbones.23
Biological evaluation
For a first biological evaluation tonantzitlolone A (1) and its
derivatives were subjected to in vitro biological testing of their
anti-proliferative activity on the mouse fibroblasts cell line
L-929, the Potorous tridactylus cell line PtK2, and the human
breast cancer cell line MCF-7. This biological evaluation indi-
cated moderate low-µM activity against cultured mammalian
cells of different origin. The results from these tests are given
as values for the half-maximal cell growth inhibitory concen-
tration (IC50, Table 2).
Our finding that tonantzitlolone and its enantiomer are
able to block kinesin-5 was based on an earlier observation.
When PtK2 potoroo kidney cells were incubated for 18 h
with 21.5 µM of 1 dissolved in methanol, ∼20% of mitotic
cells were arrested in mitosis and showed an unphysio-
logical monoastral half spindle instead of a normal bipolar
spindle apparatus. Such a monoastral phenotype is associ-
ated with the inhibition of the molecular motor protein
kinesin-5 (also known as Kif11, Eg5 or kinesin spindle
protein KSP).6
In order to link the anti-proliferative activity of the new
derivatives with the established biological target found for
tonantzitlolone (1), we also studied the effect of tonantzitlo-
lone derivatives 25, 29, 32, 33, 34, 37, 42, and 48 on mitotic
spindle formation of PtK2 potoroo kidney cells. While normal
spindles show a symmetrical bipolar structure, tonantzitlolone
and also derivatives of it induced the formation of monopolar
half-spindles. This effect was most pronounced with derivative
32, which was also the most active anti-proliferative one. One
third of the mitotic spindles counted had a half-spindle shape
at a given concentration of 19 µM. But our preliminary investi-
gation on the relation between IC50 and the degree of half-
spindle formation could not show a significant correlation of
these two parameters. Thus, we cannot exclude additional
effects (Fig. 2).5
Conclusions
In summary, the present work discloses the total synthesis of
tonantzitlolone A and the preparation of a small library of
several tonantzitlolone derivatives modified at C4, C8 and
C10, respectively. Compared to tonantzitlolone A, many of
these new derivatives show similar or improved antiprolifera-
tive activity towards mammalian cell lines in the lower micro-
molecular range. Particularly, the allyl oxime 31 and the
semicarbazone 32 showed clearly higher activities than the
parent natural product. 32 was found to be 10-fold more
potent. In this case we linked the activity to a high degree of
monoastral half-spindle formation which suggests inhibition
of the mitotic motor protein kinesin-5 as reported before.5
A more reliable statement about the link between IC50 and
kinesin-5 inhibition can only be made after measuring the
inhibitory activity on the target itself. Although the antiproli-
ferative activities are not in the range of what one expects
from chemotherapeutics the study reveals that tonantzitlolone
can be modified in various positions with improved activity
which paves the way for finding more potent derivatives in the
future.
Scheme 7 Preparation of tonantzitlolone derivative 48. Reagents and
conditions: (a) NaHMDS, THF, 0 °C, 0.5 h, then THF, TBAF* 3 H2O, 0 °C,
20 min (7%).
Table 2 Half-maximal anti-proliferative activity IC50 [µM] of 1, 25, 26,
27, 29–38, 40, 42, 44, 45 and 48 with mammalian cell lines. Values
shown are means of two determinations in parallel; L-292 (mouse fibro-
blasts), PtK2 (kidney cell line of a potoroo), MCF-7 (human breast cancer
cell line)
1 25 26a 27 29b 30 31 (37c) 32 33
L-929 >86 54 94 43 11 31 13 (58) 10 32
PtK2 43 >108 22 — 11 — 6 (6) 4 37
MCF-7 — >108 >108 — — >83 9 (—) 15 14
34 35 36 38 40 42 44 45 48
L-929 15 31 46 >86 69 33 7 7 9
PtK2 13 17 10 — 30 13 24 37 8
MCF-7 8 11 12 — >79 >66 17 — 12
a ent-26 (IC50 with L-929 > 108 μM). b ent-29 (IC50 with L-929 > 86 μM).
c Ring opened lactol.
Fig. 2 Derivatives of tonantzitlolone induce half-spindle formation as
was observed with the parent compound. (A) PtK2 potoroo kidney cells
with a mitotic cell in the centre showing a bipolar spindle. (B) A mono-
polar half-spindle was induced after incubation with 25. Since we did
not find a significant correlation between growth inhibitory activity and
influence on spindle formation there may be additional biological
targets involved. Microtubules are shown in green, DAPI labeled DNA is
shown in blue.
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The description of the synthetic protocols, the analytic data
and the procedure for the biological evaluations are found in
the ESI.†
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